Stockreport

Bavarian Nordic Announces Initiation of Clinical Trial Evaluating the Combination Therapy of CV301 and Durvalumab in Metastatic Colorectal and Pancreatic Cancers

BAVARIAN NORDIC R/I S/ADR  (BVNRY) 
NASDAQ:AMEX Investor Relations: bavarian-nordic.com/investor.aspx
PDF Investigator-led study has commenced dosing Immunotherapy candidate CV301 is now being assessed in three clinical trials in combination with checkpoint inhibitors in mul [Read more]